Imperial College London Diabetes & Endocrine Centre Unveils New Name to Reflect Comprehensive Endocrine Care Expertise

• Imperial College London Diabetes & Endocrine Centre unveils updated brand identity to reflect a fuller spectrum of endocrine care.
• The rebrand reinforces the centre’s position as the region’s largest hub for diabetes and hormonal health, with 50+ UK and US-certified endocrinologists across four strategic locations in the UAE.

Abu Dhabi, United Arab Emirates: Imperial College London Diabetes Centre, part of the globally recognized M42 group, has officially rebranded to Imperial College London Diabetes & Endocrine Centre (ICLDEC), marking a decisive step forward in the centre’s evolution. This strategic change of name reflects the healthcare provider’s expanded expertise, now encompassing the fuller breadth of endocrine care alongside its established leadership in diabetes management.

Since its inception in 2006, ICLDEC has been at the forefront of diabetes care across the UAE. As a staple provider in the M42 network of trusted healthcare authorities, the centre’s tried and trusted legacy of care is now further reflected and embodied in its new identity, marking a natural evolution. This expansion reflects the integration of cutting-edge care across all endocrine disciplines, including conditions affecting metabolism, growth, fertility, and hormonal health.

With over 50 UK and US-certified endocrinologists, ICLDEC stands as the region’s largest and most respected provider of specialised care in both diabetes and endocrine disorders, offering comprehensive services across four prime locations in the UAE. This rebrand further underscores the centre’s commitment to delivering world-class, patient-centred care that evolves alongside the growing needs of the community.

Dr. Ali Anees, Chief Operating Officer of M42’s Global Patient Care Platform in the UAE and Bahrain, said: “This rebrand is a clear representation of the broad spectrum of care we provide. Endocrinology has always been a cornerstone of our services, and we’re reinforcing our leadership in both diabetes and broader endocrine care. By elevating the visibility of our endocrine expertise, we are reaffirming our leadership across both disciplines – a commitment that will be further underscored at our upcoming Diabetes & Endocrine Conference this November.”

Endocrinology lies at the core of human health, influencing nearly every aspect of life, from growth and development to metabolism and fertility. As the demand for specialised care in this field continues to grow, ICLDEC is now better equipped to provide a more comprehensive continuum of care, offering personalised, preventive, and patient-centred services that address the spectrum of critical health concerns.

With the UAE’s recent approval of GLP-1 weight-loss medications, ICLDEC has further cemented its position as a leader in this field, offering cutting-edge, integrated services such as pre- and post-bariatric care, personalised medication plans, and holistic wellness support.

 Dr. Mai Al Jaber, CEO of ICLDEC & M42’s Outpatient Care, added, “This rebrand is more than just a name change; it reflects our forward-looking vision and the ongoing achievements we strive for, ultimately, for the benefit of our patients. We are dedicated to providing lifelong care, built on a foundation of clinical expertise and innovation. By expanding our scope, we ensure that we remain the trusted partner in endocrine care, not only across the UAE but throughout the wider region.”

ICLDEC operates in Abu Dhabi, Al Ain, and Al Dhafra, offering a full spectrum of endocrinology services to a diverse patient population. The rebrand solidifies the centre’s position as a leader in comprehensive care, reaffirming its role as a trusted provider across the GCC and beyond.